Regorafenib N-oxide D3
| Product Name | Regorafenib N-oxide D3 |
|---|---|
| Alternate Names | Regorafenib Stable Isotopes, Stable Isotopes of Regorafenib |
| CAT No. | CS-O-10713 |
| CAS No. | 1333489-03-4 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 501.83 g/mol |
| Mol. For. | C₂₁H₁₂D₃ClF₄N₄O₄ |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Regorafenib |
| Purity | 99.43 |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | FC1=C(NC(NC2=CC(C(F)(F)F)=C(Cl)C=C2)=O)C=CC(OC(C=C3C(NC([2H])([2H])[2H])=O)=CC=[N]3=O)=C1 |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Regorafenib N-oxide D3 is a deuterated derivative of Regorafenib, which is an orally administered multi-kinase inhibitor used for the treatment of various types of cancer. The deuterated form is used in clinical trials to determine the metabolic fate of the parent molecule. The chemical structure of Regorafenib N-oxide D3 consists of a phenylurea moiety, a pyridine ring, and a fluorinated phenyl group.
Regorafenib N-oxide D3 is a potent inhibitor of multiple kinases including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR). It also inhibits several other kinases such as c-KIT, RET, and BRAF. By inhibiting these kinases, Regorafenib N-oxide D3 disrupts the signaling pathways that are involved in cancer cell proliferation, angiogenesis, and metastasis.
The recommended dose of Regorafenib N-oxide D3 is dependent on the specific clinical trial in which it is used. The drug is typically administered orally, and the dosage may vary based on the patient's age, weight, and medical history. Patients receiving Regorafenib N-oxide D3 should be monitored for potential side effects, which may include fatigue, hand-foot skin reaction, diarrhea, and hypertension.
In conclusion, Regorafenib N-oxide D3 is a deuterated derivative of Regorafenib that is used in clinical trials to determine the metabolic fate of the parent molecule. It is a potent inhibitor of multiple kinases involved in cancer cell proliferation, angiogenesis, and metastasis. Regorafenib N-oxide D3 is typically administered orally, and the dosage may vary based on the specific clinical trial. Patients receiving this drug should be monitored for potential side effects.
Get an Instant Quote
Related Compounds
Regorafenib 13CD3 N-Oxide | Regorafenib D3 | Regorafenib 13CD3 N-Glucuronide | Regorafenib M4 metabolite 13C6 | N-Demethyl Regorafenib D3 N-Oxide |